gatifloxacin has been researched along with Urinary Tract Infections in 22 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Urinary Tract Infections: Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study compared the clinical and bacteriologic efficacy and tolerability of gatifloxacin versus ciprofloxacin in adult patients with complicated UTIs or pyelonephritis." | 9.10 | A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. ( Auerbach, SM; Brown, GL; Cox, CE; Fox, BC; Marbury, TC; Pittman, WG; Yang, JY, 2002) |
| "To report a case of possible gatifloxacin-induced hyperglycemia in a nondiabetic middle-aged woman." | 7.72 | Possible gatifloxacin-induced hyperglycemia. ( Donaldson, AR; Finch, CK; Vandiver, JR, 2004) |
| "Minimum inhibitory concentrations (MICs) of gatifloxacin were compared with those of gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin using an agar dilution method for 400 uropathogens cultured from the urine of urological patients with complicated and/or hospital-acquired urinary tract infections (UTI)." | 7.70 | In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections. ( Hollauer, K; Kirchbauer, D; Naber, KG; Witte, W, 2000) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin were compared to ciprofloxacin in the treatment of complicated urinary tract infection in a randomised, double-blind multi-centre trial." | 6.71 | Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. ( Ankel-Fuchs, D; Bartnicki, A; Bischoff, W; Hanus, M; Milutinovic, S; Naber, KG; Schönwald, S; van Belle, F; Weitz, P, 2004) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin compared with ciprofloxacin for the treatment of acute uncomplicated lower urinary tract infection was investigated in a double-blind, randomised study, in adult female patients who received either gatifloxacin (400 mg as a single shot or 3 days of 200 mg once daily) or ciprofloxacin (250 mg given twice daily for 3 days)." | 6.71 | Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. ( Allin, DM; Ankel-Fuchs, D; Clarysse, L; Haworth, DA; Hopkins, G; James, IG; Naber, KG; Raini, C; Schneider, H; Wall, A; Weitz, P, 2004) |
| "This study compared the clinical and bacteriologic efficacy and tolerability of gatifloxacin versus ciprofloxacin in adult patients with complicated UTIs or pyelonephritis." | 5.10 | A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. ( Auerbach, SM; Brown, GL; Cox, CE; Fox, BC; Marbury, TC; Pittman, WG; Yang, JY, 2002) |
| "This case of gatifloxacin-induced seizures may reflect a class-effect phenomenon versus an effect caused by an individual fluoroquinolone." | 3.72 | Possible gatifloxacin-induced seizure. ( Lederman, JR; Quigley, CA, 2004) |
| "To report a case of possible gatifloxacin-induced hyperglycemia in a nondiabetic middle-aged woman." | 3.72 | Possible gatifloxacin-induced hyperglycemia. ( Donaldson, AR; Finch, CK; Vandiver, JR, 2004) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin were compared to ciprofloxacin in the treatment of complicated urinary tract infection in a randomised, double-blind multi-centre trial." | 2.71 | Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. ( Ankel-Fuchs, D; Bartnicki, A; Bischoff, W; Hanus, M; Milutinovic, S; Naber, KG; Schönwald, S; van Belle, F; Weitz, P, 2004) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin compared with ciprofloxacin for the treatment of acute uncomplicated lower urinary tract infection was investigated in a double-blind, randomised study, in adult female patients who received either gatifloxacin (400 mg as a single shot or 3 days of 200 mg once daily) or ciprofloxacin (250 mg given twice daily for 3 days)." | 2.71 | Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. ( Allin, DM; Ankel-Fuchs, D; Clarysse, L; Haworth, DA; Hopkins, G; James, IG; Naber, KG; Raini, C; Schneider, H; Wall, A; Weitz, P, 2004) |
| " After an oral administration in humans, gatifloxacin is well absorbed and distributed, and the majority is excreted in the urine as the unchanged form." | 2.42 | [Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent]. ( Hosaka, M, 2003) |
| " Many of the fluoroquinolone agents have once-daily dosing regimens, enhancing patient adherence." | 2.41 | The expanding role of fluoroquinolones. ( Schaeffer, AJ, 2002) |
| "Gatifloxacin has been reported to cause dysglycaemia, especially in the elderly and in diabetics." | 1.35 | Gatifloxacin-induced severe hyperglycaemia and ketoacidosis in a non-diabetic renal transplant recipient. ( Agarwal, SK; Gupta, A; Khaira, A; Tandon, N, 2009) |
| "Gatifloxacin was active against streptococci, Escherichia coli, Klebsiella pneumoniae, Moraxella catarrhalis, Haemophilus influenzae and Neisseria gonorrhoeae, with MIC(90)s of | 1.31 | In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997-1998 in Japan. ( Hosaka, M; Manda, H; Takei, M; Tsurumaki, Y, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (95.45) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 1 |
| Gagne, JJ | 1 |
| Kattinakere-Sreedhara, S | 1 |
| Fischer, MA | 1 |
| Bykov, K | 1 |
| Khaira, A | 1 |
| Gupta, A | 1 |
| Tandon, N | 1 |
| Agarwal, SK | 1 |
| Schaeffer, AJ | 1 |
| Gaines, KK | 1 |
| Matsuzaki, K | 1 |
| Watabe, E | 1 |
| Yoshimori, K | 1 |
| Shikano, M | 1 |
| Sato, Y | 1 |
| Hasegawa, M | 1 |
| Kobayashi, I | 1 |
| Hosaka, M | 2 |
| Quigley, CA | 1 |
| Lederman, JR | 1 |
| Donaldson, AR | 1 |
| Vandiver, JR | 1 |
| Finch, CK | 1 |
| Naber, KG | 3 |
| Bartnicki, A | 1 |
| Bischoff, W | 1 |
| Hanus, M | 1 |
| Milutinovic, S | 1 |
| van Belle, F | 1 |
| Schönwald, S | 1 |
| Weitz, P | 2 |
| Ankel-Fuchs, D | 2 |
| Allin, DM | 1 |
| Clarysse, L | 1 |
| Haworth, DA | 1 |
| James, IG | 1 |
| Raini, C | 1 |
| Schneider, H | 1 |
| Wall, A | 1 |
| Hopkins, G | 1 |
| Leibovitz, E | 1 |
| Straley, CM | 1 |
| Cecil, EJ | 1 |
| Herriman, MP | 1 |
| Koussa, SF | 1 |
| Chahine, SL | 1 |
| Samaha, EI | 1 |
| Riachi, MA | 1 |
| Roghmann, MC | 1 |
| Wallin, MT | 1 |
| Gorman, PH | 1 |
| Johnson, JA | 1 |
| Tsurumaki, Y | 1 |
| Manda, H | 1 |
| Takei, M | 1 |
| Hollauer, K | 1 |
| Kirchbauer, D | 1 |
| Witte, W | 1 |
| Marinella, MA | 1 |
| Jones, RN | 1 |
| Beach, ML | 1 |
| Pfaller, MA | 1 |
| Richard, GA | 1 |
| Mathew, CP | 1 |
| Kirstein, JM | 1 |
| Orchard, D | 1 |
| Yang, JY | 2 |
| Cox, CE | 1 |
| Marbury, TC | 1 |
| Pittman, WG | 1 |
| Brown, GL | 1 |
| Auerbach, SM | 1 |
| Fox, BC | 1 |
3 reviews available for gatifloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
The expanding role of fluoroquinolones.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Ga | 2002 |
[Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent].
Topics: Animals; Anti-Infective Agents; Bacteria; Clinical Trials as Topic; DNA Topoisomerase IV; Drug Resis | 2003 |
The use of fluoroquinolones in children.
Topics: Anti-Infective Agents; Child; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Humans; Im | 2006 |
4 trials available for gatifloxacin and Urinary Tract Infections
15 other studies available for gatifloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Emergency Service, Hospit | 2022 |
Gatifloxacin-induced severe hyperglycaemia and ketoacidosis in a non-diabetic renal transplant recipient.
Topics: Anti-Infective Agents; Diabetic Ketoacidosis; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; | 2009 |
What's new about gatifloxacin (Tequin)?
Topics: Anti-Infective Agents; Drug Interactions; Fluoroquinolones; Gatifloxacin; Humans; Urinary Tract Infe | 2002 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprof | 2002 |
Possible gatifloxacin-induced seizure.
Topics: Aged; Aged, 80 and over; Fluoroquinolones; Gatifloxacin; Humans; Intensive Care Units; Male; Seizure | 2004 |
Possible gatifloxacin-induced hyperglycemia.
Topics: Anti-Infective Agents, Urinary; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Middl | 2004 |
Gatifloxacin interference with opiate urine drug screen.
Topics: Anti-Bacterial Agents; False Positive Reactions; Fluoroquinolones; Gas Chromatography-Mass Spectrome | 2006 |
Generalized status epilepticus possibly induced by gatifloxacin.
Topics: Aged; Anti-Bacterial Agents; Female; Fluoroquinolones; Gatifloxacin; Humans; Status Epilepticus; Uri | 2006 |
Prevalence and natural history of colonization with fluoroquinolone-resistant gram-negative bacilli in community-dwelling people with spinal cord dysfunction.
Topics: Anti-Bacterial Agents; Carrier State; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; | 2006 |
In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997-1998 in Japan.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Fluoroquinolones; Gatifloxacin; Humans; Japa | 2000 |
In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Gatifloxaci | 2000 |
[Broad-spectrum fluoroquinolones. Passed safety tests up to now].
Topics: Aged; Anti-Infective Agents; Drug Approval; Fluoroquinolones; Gatifloxacin; Germany; Humans; Pneumon | 2001 |
[New quinolone. Better effectiveness in problem cases].
Topics: Anti-Infective Agents; Bronchitis; Fluoroquinolones; Gatifloxacin; Humans; Pneumonia, Bacterial; Tre | 2001 |
Myoclonus and generalized seizures associated with gatifloxacin treatment.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Dose-Response Relationship, Drug; Drug Administratio | 2001 |
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Cipro | 2001 |